MEI Pharma (MEIP) Issues Letter to Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- S&P and Nasdaq dip as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- S&P and Nasdaq dip as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
June 29, 2023 8:00 AM EDTHighlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs
Combined Company Well-Positioned to Make a Difference in Cancer Care With Significant Potential to Deliver Improved Therapeutic Options for Patients
Board Reiterates Recommendation to Shareholders to Vote FOR the Merger Agreement with Infinity Pharmaceuticals Ahead of the Special Meeting of MEI Pharma Shareholders on July 14, 2023
SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP) (the Company) today issued the following letter to shareholders reiterating the Board of... More
